A Retrospective Look at Drug Sensitivity Before and After Checkpoint Blockade in R/R NHL

A Retrospective Look at Drug Sensitivity Before and After Checkpoint Blockade in R/R NHL

Checkpoint-based therapies may sensitize patients to subsequent therapies.

FDA Grants Approval to New Treatment for Acute Myeloid Leukemia

FDA Grants Approval to New Treatment for Acute Myeloid Leukemia

Randomized clinical trial showed significant improvement in overall survival with glasdegib.

Azacytidine, Nivolumab Combination Provides Safe, Effective Balance in Relapsed/Refractory AML

Azacytidine, Nivolumab Combination Provides Safe, Effective Balance in Relapsed/Refractory AML

Researchers investigated the safety and efficacy of combination therapy with azacytidine and nivolumab for relapsed/refractory AML.

Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia

Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia

Researchers reviewed cancer incidence in patients with Diamond-Blackfan anemia.

G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher

G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher

A meta-analysis of 14 randomized, controlled trials was conducted to determine if combining G-CSF with intensified chemotherapy improved overall survival.

The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients

The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients

[Cancer Management and Research] Researchers sought to determine the effect of intravenous hydration on plasma methotrexate clearance on pediatric oncology patients receiving HD-MTX for ALL, NHL, or osteosarcoma.

Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma

Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma

A review of therapy options for relapsed/refractory DLBCL and FL compared SCT with chemotherapy/immunotherapy and experimental regimes. Patients fared better with SCT than other treatment modalities.

Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress

Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress

A retrospective evaluation of patients treated at a tertiary cancer center demonstrated that patients with Hodgkin lymphoma experienced periods of actionable distress in survivorship, despite a low overall distress burden.

Commission Seeks Standardized Adverse Event Assessments in Hematologic Malignancies

Commission Seeks Standardized Adverse Event Assessments in Hematologic Malignancies

A snapshot of an international Commission's report on the issues inherent with adverse event reports of hematologic malingnancies in clinical trials.

Leukemia Risk in Children, Maternal Use of Hormonal Contraception Linked in Population Study

Leukemia Risk in Children, Maternal Use of Hormonal Contraception Linked in Population Study

A prospective cohort study from Denmark investigated the link between maternal hormonal contraception use before — more than 3 months and within 3 months — and during pregnancy and risk of leukemia in their children.

Risk Factors for Higher-Grade Transformation in Marginal Zone Lymphomas Identified

Risk Factors for Higher-Grade Transformation in Marginal Zone Lymphomas Identified

In a retrospective evaluation, investigators sought to identify risk factors for higher-grade transformation in patients with marginal zone lymphomas.

Cost of Brentuximab Vedotin as First-Line Therapy for Advanced Hodgkin Lymphoma Prohibitive

Cost of Brentuximab Vedotin as First-Line Therapy for Advanced Hodgkin Lymphoma Prohibitive

Although brentuximab vedotin offers clinical benefit over bleomycin in first-line treatment of adults with advanced Hodgkin lymphoma, investigators find the drug is not cost-effective.

Navigation at the End of Therapy: A Crucial Transition in Lymphoma Treatment

Navigation at the End of Therapy: A Crucial Transition in Lymphoma Treatment

A nurse-led study explored the significance of nurse navigators for patients with lymphoma approaching their transition from acute care to survivorship care.

Risk of Relapse Up for Young Adults With Leukemia

Risk of Relapse Up for Young Adults With Leukemia

Increased risk of on-therapy relapse, relapse after completing therapy versus children with ALL

Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma

Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma

A retrospective follow-up study demonstrates that tandem autologous-allogeneic is safe for standard and high-risk multiple myeloma. However, benefits do not extend to patients with ultra-high-risk disease and those with disease progression after autologous HCT.

Belly Fat Is a Better Risk Calculator for Blood Cancers Than BMI

Belly Fat Is a Better Risk Calculator for Blood Cancers Than BMI

BMI often relies on self-reported weight and height values, and therefore may be a less accurate predictor of cancer risk than alternative body composition measurements.

Newer Hodgkin Lymphoma Regimens Are Less Toxic, But Still Impose Reproductive Risks

Newer Hodgkin Lymphoma Regimens Are Less Toxic, But Still Impose Reproductive Risks

A substudy of a multinational study sought to determine the risk to ovarian function with ABVD, AVD, and BEACOPP regimens on ovarian function in women with Hodgkin lymphoma.

Infections in Primary Immune Thrombocytopenia Associated With Low Platelet Count

Infections in Primary Immune Thrombocytopenia Associated With Low Platelet Count

A retrospective study of platelet- and infection-related data from patients with ITP revealed the influence platelet levels have on infections as well as efficacy of transfusions.

Hematologic Cancers: 8 Tips Oncology Nurses Should Share with Caregivers

Hematologic Cancers: 8 Tips Oncology Nurses Should Share with Caregivers

The family and friends of a patient diagnosed with blood cancer are often eager to help but unsure how to go about it. This article offers 8 practical tips oncology nurses can share with caregivers.

Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT

Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT

An international multidisciplinary panel of experts in pediatric oncology and infectious diseases convened to develop recommendations for the prevention and treatment of C difficile infection in pediatric patients with cancer or who are undergoing HSCT.

FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia

FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia

Lumoxiti, a CD22-directed cytotoxin, has been approved for adult patients who have had at least two prior therapies for the disease.

Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT

Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT

In the EBMT ALWP study, researchers sought to determine the efficacy of myeloablative conditioning to reduce the risk for post allogeneic HCT in patients with sAML without significantly increasing non-relapse mortality.

Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin

Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin

A retrospective study evaluated the efficacy vs pulmonary toxicity of brentuximab vedotin for relapsed or refractory Hodgkin lymphoma in pediatric patients.

Rituximab Maintenance Improved Long-Term Survival in Elderly With Follicular Lymphoma

Rituximab Maintenance Improved Long-Term Survival in Elderly With Follicular Lymphoma

A retrospective analysis of outcomes demonstrated the influence of rituximab maintenance after R-CHOP or R-CVP for follicular lymphoma in elderly patients.

Insurance Status Influences Overall Survival in Follicular Lymphoma

Insurance Status Influences Overall Survival in Follicular Lymphoma

Outcomes data demonstrated the impact of socioeconomic status and insurance coverage on outcomes for patients with follicular lymphoma by age (younger than 65 and 65 and older).

Fostamatinib Appears Effective for Immune Thrombocytopenia

Fostamatinib Appears Effective for Immune Thrombocytopenia

Researchers found that stable responses occurred in 18 percent of patients on fostamatinib, versus 2 percent on placebo.

Too Much Physical Activity During Therapy for Pediatric ALL Decreases Cognitive Function

Too Much Physical Activity During Therapy for Pediatric ALL Decreases Cognitive Function

Using a longitudinal parallel-process model, researchers evaluated the impact of physical activity on symptoms, physical activity, and cognitive function in children with ALL undergoing chemotherapy.

RiBVD Effective in the First-Line Setting for Mantle Cell Lymphoma

RiBVD Effective in the First-Line Setting for Mantle Cell Lymphoma

Researchers sought to determine if the newly formed regimen RiBVD was effective and tolerable in patients older than 65 with mantle cell lymphoma.

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

A phase 1 dose-finding study determined which of 2 lurbinectedin dosing schedules had greater effectiveness and fewer AEs in patients with relapsed/refractory MDS or AML.

Lenalidomide Plus R-CHOP Effective in High-Burden Follicular Lymphoma

Lenalidomide Plus R-CHOP Effective in High-Burden Follicular Lymphoma

A phase 2 study was conducted to determine the effectiveness of adding lenalidomide to R-CHOP as a first-line treatment for high-burden follicular lymphoma.

Ibrutinib Compared With Chemotherapy in Treatment-Naive CLL

Ibrutinib Compared With Chemotherapy in Treatment-Naive CLL

Ibrutinib monotherapy may reduce the need for chemotherapy for some treatment-naive patients with chronic CLL, research indicates.

Pre-HSCT Conditioning May Improve Physical Functioning in Hematologic Cancers

Pre-HSCT Conditioning May Improve Physical Functioning in Hematologic Cancers

In this retrospective study, researchers assessed the outcomes of 88 patients with hematologic disease who underwent HSCT.

Bendamustine Plus Obinutuzumab, Venetoclax Shows Therapeutic Potential in CLL

Bendamustine Plus Obinutuzumab, Venetoclax Shows Therapeutic Potential in CLL

Findings in an ongoing phase 2 trial demonstrate that a sequential regimen of these agents has significant potential to improve depth of response and outcomes for patients with chronic lymphocytic leukemia.

Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia

Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia

A single-center retrospective study assessed the effectiveness of serum albumin levels and BMI as prognostic measures in patients with AML.

Nonmyeloablative/Reduced-Intensity Conditioning May Reduce Mucositis in HCT

Nonmyeloablative/Reduced-Intensity Conditioning May Reduce Mucositis in HCT

Researchers sought to determine if NMA or reduced-intensity conditioning with busulfan improved severity/duration of oral mucositis compared with myeloablative conditioning in patients with hematologic cancer undergoing HCT.

FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma

FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma

The manufacturer of daratumumab, a CD38-directed antibody for the treatment of multiple myeloma, has submitted a sBLA and a type II variation to the US FDA and European Medicines Agency, respectively, for approval of a split dosing regimen.

8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers

8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers

In an open-label study, researchers sought to determine the optimal amount of bed rest after intrathecal chemotherapy for patients with hematologic cancers.

Health Domains May Mediate Psychological Risk in Survivors of Childhood Leukemia

Health Domains May Mediate Psychological Risk in Survivors of Childhood Leukemia

A population study of a PETALE cohort demonstrated an association between functional health domains and psychological risk in adolescent and adult survivors of cALL.

FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma

FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma

Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

Researchers sought to determine the impact of intensive chemotherapy on achieving complete remission and overall survival among patients with MDS or sAML.

Long-Term Azithromycin May Increase Risk of Relapse of Blood Cancers After HSCT

Long-Term Azithromycin May Increase Risk of Relapse of Blood Cancers After HSCT

US FDA issues a recommendation on use of azithromycin in patients with hematologic malignancies who have undergone HSCT.

Effect of HSCT on HRQOL and Posttraumatic Stress in Young Adult Cancer Survivors

Effect of HSCT on HRQOL and Posttraumatic Stress in Young Adult Cancer Survivors

Study sought to determine the health-related QOL and posttraumatic stress symptoms in adolescent and young adult cancer survivors post-HSCT compared with their healthy peers.

Lorazepam Did Not Improve CINV in Pediatric Acute Lymphoblastic Leukemia

Lorazepam Did Not Improve CINV in Pediatric Acute Lymphoblastic Leukemia

A retrospective chart review was conducted to determine if adding lorazepam to granisetron would improve CINV prevention in pediatric patients with newly diagnosed ALL.

Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era

Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era

[Cancer Management and Research] A review of fertility complications induced by chemotherapy and radiotherapy, as well as possible treatment options for HL patients with fertility problems.

Bleeding Disorder Treatments: von Willebrand Disease

Treatment options for von Willebrand Disease (VWD).

Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL

Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL

A new analysis of FAB/LMB 96 looked into factors associated with shortened OS among children and adolescents with B-NHL.

Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma

Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma

Although involved-field radiotherapy (IFRT) has a high level of disease control in patients with follicular lymphoma, relapse frequently occurs; therefore, researchers sought to determine if adding chemotherapy would improve progression-free survival.

Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant

Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant

In this study, researchers investigated the effects of exercise on physical and psychological recovery after autoHSCT for multiple myeloma.

De-Escalation or Stoppage May Be Effective After Response to TKI Therapy in CML

De-Escalation or Stoppage May Be Effective After Response to TKI Therapy in CML

De-escalation of TKI therapy may be an effective management strategy among patients with CML who have responded to therapy.

Remission Duration Predicts Long-Term Outcomes in Chronic Lymphocytic Leukemia

Remission Duration Predicts Long-Term Outcomes in Chronic Lymphocytic Leukemia

A retrospective study sought to evaluate outcomes for patients with CLL who were treated with FCR, a highly effective treatment, and initially had refractory disease, experienced relapse early, or were unable to complete therapy due to toxicity.

Low-Dose Dasatinib for Chronic-Phase CML Safe, Effective With Fewer Adverse Events

Low-Dose Dasatinib for Chronic-Phase CML Safe, Effective With Fewer Adverse Events

In this study, researchers assigned 75 patients with newly diagnosed Philadelphia chromosome (Ph)-positive CML-CP to receive dasatinib 50 mg once daily.

Navigating Patients with Hematologic Malignancies

Navigating Patients with Hematologic Malignancies

Patients with hematologic cancers often require a combination of inpatient and outpatient care. The oncology nurse navigator is an ideal care provider to help patients manage their care and transitions between care settings, according to a presentation at the 2018 ONA Navigation Summit.

Andrographolide Potentiates the Antitumor Effect of Topotecan in Acute Myeloid Leukemia Cells Through an Intrinsic Apoptotic Pathway

Andrographolide Potentiates the Antitumor Effect of Topotecan in Acute Myeloid Leukemia Cells Through an Intrinsic Apoptotic Pathway

[Cancer Management and Research] In this study, researchers explored the potential of andrographolide and topotecan, separately and together, in the in vitro treatment of the U937 acute myeloid leukemic cell line.

R-THP-COP a New Therapeutic Alternative for Diffuse Large B Cell Lymphoma

R-THP-COP a New Therapeutic Alternative for Diffuse Large B Cell Lymphoma

Results of a prospective phase 3 study demonstrated noninferiority of R-THP-COP for diffuse large B cell lymphoma to the standard of care, suggesting the regimen may be an alternative option for these patients.

QOL, Fatigue, but Not Physical Performance, Return to Normal After AML Treatment

QOL, Fatigue, but Not Physical Performance, Return to Normal After AML Treatment

In a prospective, longitudinal study, researchers investigated the potential for quality of life, fatigue, and physical functioning to return to previous levels in patients with AML after treatment.

Relapsed/Refractory DLBCL Added to Approved CAR-T Cell Therapy Indications

Relapsed/Refractory DLBCL Added to Approved CAR-T Cell Therapy Indications

FDA approval was based on results of the single-arm phase 2 JULIET clinical trial.

Weekend Admission for Acute Leukemia Negatively Affects Mortality Rate

Weekend Admission for Acute Leukemia Negatively Affects Mortality Rate

An assessment of more than 71,000 patients with leukemia demonstrated the difference in outcomes for patients admitted to hospital on the weekend vs weekday. Findings were presented at the 2018 ASCO Annual Meeting.

Radiation-Induced Esophagitis: A Common, Debilitating Clinical Challenge in Thoracic Radiotherapy

Radiation-Induced Esophagitis: A Common, Debilitating Clinical Challenge in Thoracic Radiotherapy

A review of current options and ongoing trials for managing ARIE, a common esophageal adverse effect caused by radiotherapy to the thoracic region for lung, breast, or head and neck cancers, or lymphoma.

Dexrazoxane May Reduce Cardiotoxicity in Pediatric AML

Dexrazoxane May Reduce Cardiotoxicity in Pediatric AML

Children's Oncology Group study reported on the effect of dexrazoxane on cardiotoxicity of anthracycline-containing regimens in pediatric patients with AML at the 2018 ASCO Annual Meeting.

Dual Inhibitor for Treating CLL/SLL, Follicular Lymphoma Granted Priority Review

Dual Inhibitor for Treating CLL/SLL, Follicular Lymphoma Granted Priority Review

Duvelisib, a first-in-class dual inhibitor of PI3K-delta and -gamma, was evaluated in patients with relapsed/refractory CLL/SLL and in patients with refractory indolent non-Hodgkin lymphoma.

Palliative Issues Inadequately Addressed Among Hospitalized Cancer Patients

Palliative Issues Inadequately Addressed Among Hospitalized Cancer Patients

Consultations for palliative care for hospitalized highly symptomatic patients with cancer is low regardless of curability or whether patient has hematologic or solid cancer, a study presented at 2018 ASCO has shown.

PET Use May Allow Early Treatment Adjustment in Non-Hodgkin Lymphoma

PET Use May Allow Early Treatment Adjustment in Non-Hodgkin Lymphoma

The ability to make early adjustments to treatment has the potential to improve survival.

Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers

Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers

A newly developed web site, described in a presentation at the 2018 ONS Annual Congress, aims to help nurses and patients explore clinical trial options for patients with hematologic cancers.

Developing Multidisciplinary Algorithm for AML Induction in Elderly Benefits Nurses

Developing Multidisciplinary Algorithm for AML Induction in Elderly Benefits Nurses

Teaming up with multiple specialists to create an algorithm for managing AML in older patients improved clinician knowledge as well as provided patient-centered care, a presentation at 2018 ONS Annual Congress has shown.

Low Level Laser Therapy May Prevent Oral Mucositis During HSCT Conditioning

Low Level Laser Therapy May Prevent Oral Mucositis During HSCT Conditioning

Researchers assessed the effectiveness of low level laser therapy in preventing or minimizing oral mucositis in patients with hematologic cancers preparing to undergo HSCT. Results were presented at the 2018 ONS Annual Congress.

Symptoms, Quality of Life May Improve During Hospitalization for Acute Leukemia

Symptoms, Quality of Life May Improve During Hospitalization for Acute Leukemia

Results of a prospective, longitudinal study presented at 2018 ONS Congress demonstrate improvement from baseline to discharge patients with acute leukemia who receive induction chemotherapy in hospital.

FDA Approves Blincyto for B-Cell Precursor ALL in Remission With MRD Presence

FDA Approves Blincyto for B-Cell Precursor ALL in Remission With MRD Presence

Accelerated approval was granted by the FDA based on the results of a single-arm trial.

Class Preps Patients With AML for Successful At-Home Symptom Management and Self-Care

Class Preps Patients With AML for Successful At-Home Symptom Management and Self-Care

A presentation at 2018 ONS Congress described the success of a class focused on preparing patients and their families to management their care after discharge.

Nurse-led Interventions Improve Quality of Life for Lymphoma Survivors

Nurse-led Interventions Improve Quality of Life for Lymphoma Survivors

Patients with lymphoma were interviewed to determine their evaluation of a program that offered continuing clinical care with a nurse-led intervention in the early months of survivorship.

Management of Relapsed/Refractory Marginal Zone Lymphoma: Focus on Ibrutinib

Management of Relapsed/Refractory Marginal Zone Lymphoma: Focus on Ibrutinib

[Cancer Management and Research] A review of marginal zone lymphomas, a common and varied group of hematologic malignancies, and their treatment, with a focus on the Bruton's tyrosine kinase ibrutinib.

Long-term Survival Improving Over Time in Advanced Hodgkin Lymphoma

Long-term Survival Improving Over Time in Advanced Hodgkin Lymphoma

A review of SEER data revealed trends in incidence of advanced Hodgkin lymphoma, discrepancies among subgroups, and survival over 3 decades.

Venetoclax Found Effective in Relapsed/Refractory Chronic Lymphocytic Leukemia

Venetoclax Found Effective in Relapsed/Refractory Chronic Lymphocytic Leukemia

A group of Australian researchers report study findings that demonstrate a significant improvement in PFS in patients with relapsed/refractory CLL treated with venetoclax plus rituximab compared with the standard care.

Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers

Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers

Slight changes in taste perceptions are noted in patients undergoing HSCT for hematologic cancers. In this study, researchers sought to determine how these changes affect quality of life and nutritional intake.

Fifth Indication for Brentuximab Vedotin Is a First for cHL Therapy in 40+ Years

Fifth Indication for Brentuximab Vedotin Is a First for cHL Therapy in 40+ Years

FDA approval was granted based on findings from the open-label phase 3 ECHELON-1 study.

18F-FDG PET/CT Accurately Identifies Bone Marrow Involvement in Pediatric Hodgkin's Lymphoma

18F-FDG PET/CT Accurately Identifies Bone Marrow Involvement in Pediatric Hodgkin's Lymphoma

Researchers conducted a retrospective study to assess 18F-FDG PET/CT vs bone marrow biopsy to detect bone marrow involvement among pediatric patients with Hodgkin lymphoma.

Intensified Reduced-Intensity Conditioning May Improve Outcomes in CBT

Intensified Reduced-Intensity Conditioning May Improve Outcomes in CBT

Researchers compared survival outcomes of thiotepa-based intensified RIC vs standard RIC among patients undergoing cord-blood transplantation (CBT).

Lenalidomide Alone or With Dexamethasone Effective in Relapsed Multiple Myeloma

Lenalidomide Alone or With Dexamethasone Effective in Relapsed Multiple Myeloma

A study of 133 patients with multiple myeloma who experienced a first relapse compared the efficacy of long-term therapy lenalidomide alone vs with dexamethasone.

Redefining Prognosis for Hematologic Cancers in Older Adults by Age

Redefining Prognosis for Hematologic Cancers in Older Adults by Age

A report on how variations in the effects of geriatric syndromes and aging can affect treatment modality choices and outcomes for the eldest older adults with hematologic cancers.

Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments

Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments

Study data suggest that cognitive impairments may be associate with worse survival among patients with hematologic cancer.

FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment

FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment

The US FDA granted approval to fostamatinib (Tavalisse), a kinase inhibitor, for the treatment of thrombocytopenia in patients with chronic IPT who have had an insufficient response to a previous treatment.

Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma

Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma

In a case-control study using PEDS data, researchers determined the impact of inactivity on risk for Hodgkin lymphoma and non-Hodgkin lymphoma.

Bax, Bcl-2, and Bax/Bcl-2 as Prognostic Markers in Acute Myeloid Leukemia: Are We Ready for Bcl-2-Directed Therapy?

Bax, Bcl-2, and Bax/Bcl-2 as Prognostic Markers in Acute Myeloid Leukemia: Are We Ready for Bcl-2-Directed Therapy?

[Cancer Management and Research] This report presents an assessment of the relationship of Bax/Bcl-2 expression and the clinical response of patients with AML treated with cytarabine plus daunorubicin, and their potential as biomarkers to predict chemotherapeutic outcomes.

Elevated Pre-HCT Iron Levels Predictive of Worse Survival Outcomes in AML/MDS

Elevated Pre-HCT Iron Levels Predictive of Worse Survival Outcomes in AML/MDS

The ALLIVE trial sought to determine if eLPI levels were predictive of iron-related toxicity and mortality after HCT in patients with AML or MDS.

1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML

1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML

Although many TKIs have well-documented cardiotoxic effects, results of a single-center prospective study that assessed effects of 1 year of therapy with imatinib or nilotinib in patients with CML demonstrated safety and efficacy of the 2 agents in this population.

Risk of Secondary Cancers With CML Linked to Disease, Not Treatment

Risk of Secondary Cancers With CML Linked to Disease, Not Treatment

This study examined the risk of secondary cancers among patients with CML who were treated with TKIs.

Blinatumomab Indications Expanded to Include MRD+-B-Cell Precursor ALL

Blinatumomab Indications Expanded to Include MRD+-B-Cell Precursor ALL

The US FDA approved expanding the indications for the agent to include pediatric and adult patients with B-cell precursor ALL who have minimal residual disease during or after treatment.

Overtreatment a Concern With RAI for Well-Differentiated Thyroid Cancer

Overtreatment a Concern With RAI for Well-Differentiated Thyroid Cancer

In a study from the Cleveland Clinic, researchers investigated the association between well-differentiated thyroid cancer and risk for AML or CML in those patients treated with radioactive iodine.

Secondary Outcome Shows Inotuzumab Ozogamicin for B-cell ALL Improves Health-Related QOL

Secondary Outcome Shows Inotuzumab Ozogamicin for B-cell ALL Improves Health-Related QOL

Inotuzumab ozogamicin (InO) use may have quality of life benefits for patients with R/R B-cell ALL, as well as producing improved clinical outcomes.

FDA Expands Nilotinib Indication to Include Pediatric Chronic Myeloid Leukemia

FDA Expands Nilotinib Indication to Include Pediatric Chronic Myeloid Leukemia

Based on results of 2 prospective studies, the FDA approved the use of nilotinib in pediatric patients older than 1 year with newly diagnosed Ph+ CML-CP and those with TKI-intolerant or resistant disease.

Patients Identify Critical Elements of Support in Hematologic Cancers

Patients Identify Critical Elements of Support in Hematologic Cancers

A cross-sectional study asked patients with hematologic cancers to name the components of care they felt were most crucial to their perception of optimal care.

Treatment-Free Remission in Chronic Phase CML Achieved With First-Line Nilotinib

Treatment-Free Remission in Chronic Phase CML Achieved With First-Line Nilotinib

Some patients with chronic myeloid leukemia in chronic phase maintained TFR after receiving nilotinib, according to data from the ENESTfreedom study.

Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms

Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms

Researchers investigated the antileukemic activity of metformin and ruxolitinib alone and in combination in patients with myeloproliferative neoplasms.

Bisphosphonate Therapy Underutilized in Multiple Myeloma Bone Disease Management

Bisphosphonate Therapy Underutilized in Multiple Myeloma Bone Disease Management

A retrospective study evaluated timing, frequency, dosing, and other factors related to bisphosphonate therapy in patients with multiple myeloma.

Chronic Lymphocytic Leukemia Responds Better to Obinutuzumab Than Other Monoclonal Antibodies

Chronic Lymphocytic Leukemia Responds Better to Obinutuzumab Than Other Monoclonal Antibodies

Researchers used mouse cells to determine activation levels of FcγRIIIa and FcγRI using obinutuzumab, rituximab and ofatumumab.

Second-line Nilotinib May Lead to Treatment-Free Remission in Chronic Phase CML

Second-line Nilotinib May Lead to Treatment-Free Remission in Chronic Phase CML

Results of the ENESTop study demonstrate the potential for patients with CML who had deep molecular response to achieve long-term treatment-free remission (TFR) after second-line nilotinib, increasing the focus of TFR as a therapeutic outcome.

Self-efficacy Measure May Be Used to Drive Interventions Post-SCT in Hematologic Cancers

Self-efficacy Measure May Be Used to Drive Interventions Post-SCT in Hematologic Cancers

Researchers present findings of a study assessing the value of SESM evaluations in patients with hematologic cancer prior to undergoing SCT at the NACNS 2018 Annual Conference.

Cardiovascular Disease Risks Greater With ITP, Especially After Splenectomy

Cardiovascular Disease Risks Greater With ITP, Especially After Splenectomy

Idiopathic thrombocytopenic purpura (ITP) may be linked to an increased risk of cardiovascular disease, but studies have not been conclusive.

Monitoring Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax

Monitoring Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax

What are key monitoring guidelines for patients with CLL being treated with venetoclax?

Complementary and Alternative Medicine Practices of Lymphoma Survivors in South Korea

Complementary and Alternative Medicine Practices of Lymphoma Survivors in South Korea

A study from South Korea determined the prevalence and type of CAM practices lymphoma survivors used for various purposes including ease symptoms, augment treatment, boost immunity, and gain a sense of control.

Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies

Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies

A review of management approaches to Hodgkin lymphoma in Europe vs the United States/North America demonstrates that although some differences exist, worldwide studies that would enhance patient outcomes are feasible.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs